CN105431738B - 胃癌的预后预测模型的建立方法 - Google Patents

胃癌的预后预测模型的建立方法 Download PDF

Info

Publication number
CN105431738B
CN105431738B CN201480024783.5A CN201480024783A CN105431738B CN 105431738 B CN105431738 B CN 105431738B CN 201480024783 A CN201480024783 A CN 201480024783A CN 105431738 B CN105431738 B CN 105431738B
Authority
CN
China
Prior art keywords
expression
mrna
snp
gene
kras
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480024783.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105431738A (zh
Inventor
许镛敏
卢圣勳
徐振锡
郑载镐
朴恩成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novomics Co ltd
Original Assignee
Nova Meeks Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nova Meeks Ltd filed Critical Nova Meeks Ltd
Publication of CN105431738A publication Critical patent/CN105431738A/zh
Application granted granted Critical
Publication of CN105431738B publication Critical patent/CN105431738B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Data Mining & Analysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Software Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Databases & Information Systems (AREA)
CN201480024783.5A 2013-04-05 2014-04-07 胃癌的预后预测模型的建立方法 Expired - Fee Related CN105431738B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020130037336A KR101501826B1 (ko) 2013-04-05 2013-04-05 위암에 대한 예후 예측 모형의 제조방법
KR10-2013-0037336 2013-04-05
PCT/KR2014/002959 WO2014163445A1 (ko) 2013-04-05 2014-04-07 위암에 대한 예후 예측 모형의 제조방법

Publications (2)

Publication Number Publication Date
CN105431738A CN105431738A (zh) 2016-03-23
CN105431738B true CN105431738B (zh) 2017-11-03

Family

ID=51658661

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480024783.5A Expired - Fee Related CN105431738B (zh) 2013-04-05 2014-04-07 胃癌的预后预测模型的建立方法

Country Status (6)

Country Link
US (1) US20160040253A1 (https=)
EP (1) EP2982986B1 (https=)
JP (1) JP6356217B2 (https=)
KR (1) KR101501826B1 (https=)
CN (1) CN105431738B (https=)
WO (1) WO2014163445A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018094569A1 (zh) * 2016-11-22 2018-05-31 深圳华大基因研究院 多肽及其应用
WO2018098636A1 (zh) * 2016-11-29 2018-06-07 深圳华大基因研究院 多肽及其应用
KR102127449B1 (ko) * 2017-02-08 2020-06-26 사회복지법인 삼성생명공익재단 생존율 예측 모델 생성 방법, 장치 및 컴퓨터 프로그램
CN108504732A (zh) * 2017-02-27 2018-09-07 复旦大学附属华山医院 一种建立胃癌的风险预测模型的方法
KR101940657B1 (ko) * 2017-04-24 2019-01-21 (주) 노보믹스 위암의 생물학적 특성에 기반한 군 구분 및 예후 예측 시스템
CN107090503B (zh) * 2017-04-27 2020-06-19 元码基因科技（北京）股份有限公司 探针组合物、基因捕获芯片、试剂盒及其应用
CN107641653B (zh) * 2017-10-20 2021-02-19 南方医科大学南方医院 Macc1-as1探针在制备用于预测胃癌临床预后的诊断试剂中的应用
CN113851185B (zh) * 2021-11-29 2022-04-19 求臻医学科技（北京）有限公司 一种用于非小细胞肺癌患者免疫治疗的预后评估方法
CN115820853A (zh) * 2022-09-22 2023-03-21 中国医科大学附属第一医院 一种malat1基因snp位点及其作为胃癌预后标志物的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012081898A2 (ko) * 2010-12-13 2012-06-21 사회복지법인 삼성생명공익재단 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530017A (ja) * 2004-03-02 2007-11-01 ザ ジョンズ ホプキンス ユニバーシティ ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
ES2553442T3 (es) * 2006-01-05 2015-12-09 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón
CA2648021A1 (en) * 2006-03-31 2007-10-11 Ordway Research Institute, Inc. Prognostic and diagnostic method for cancer therapy
US8680041B2 (en) * 2006-10-26 2014-03-25 Genentech, Inc. Genetic variations associated with tumors
EP2288728A4 (en) * 2008-05-15 2011-11-02 Univ Southern California GENOTYP AND EXPRESSION ANALYSIS FOR USE IN PROGNOSIS AND THERAPY SELECTION
KR20120061010A (ko) * 2010-11-02 2012-06-12 서울대학교산학협력단 위암 진단 방법
CN103906848B (zh) * 2011-08-18 2016-03-02 雀巢产品技术援助有限公司 用于检测等位变体的组合物和方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012081898A2 (ko) * 2010-12-13 2012-06-21 사회복지법인 삼성생명공익재단 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine;Joanna D Holbrook et al;《Journal of Translational Medicine》;20110725;第9卷;第1-13页 *
Prognostic significance of genetic alterations detected by high-density single nucleotide polymorphism array in gastric cancer;Motohisa Tada et al;《cancer science》;20100312;第1261-1269页 *
Relevance of MET activation and genetic alterations of KRAS andE-cadherinforcetuximabsensitivity of gastric cancer cell lines;Stefan Heindl;《J Cancer Res Clin Oncol》;20120131;第138卷;第843-858页 *
The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation;UTA DREBBER et al;《ONCOLOGY REPORTS 》;20080601;第19卷;第1477-1483页 *

Also Published As

Publication number Publication date
KR20140121524A (ko) 2014-10-16
KR101501826B1 (ko) 2015-03-13
WO2014163445A1 (ko) 2014-10-09
EP2982986A1 (en) 2016-02-10
JP2016515390A (ja) 2016-05-30
CN105431738A (zh) 2016-03-23
EP2982986B1 (en) 2019-01-30
US20160040253A1 (en) 2016-02-11
EP2982986A4 (en) 2016-12-07
JP6356217B2 (ja) 2018-07-11

Similar Documents

Publication Publication Date Title
CN105431738B (zh) 胃癌的预后预测模型的建立方法
JP6190434B2 (ja) 化学療法剤に対する応答を予測するための遺伝子発現マーカー
US20230366034A1 (en) Compositions and methods for diagnosing lung cancers using gene expression profiles
EP2504451B1 (en) Methods to predict clinical outcome of cancer
JP4938672B2 (ja) ｐ５３の状態と遺伝子発現プロファイルとの関連性に基づき、癌を分類し、予後を予測し、そして診断する方法、システム、およびアレイ
JP2018068299A (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
CN103403543A (zh) 结肠癌基因表达签名及使用方法
US9890430B2 (en) Copy number aberration driven endocrine response gene signature
US20250137066A1 (en) Compostions and methods for diagnosing lung cancers using gene expression profiles
EP1683862B1 (en) Microarray for assessing neuroblastoma prognosis and method of assessing neuroblastoma prognosis
US20090297506A1 (en) Classification of cancer
KR101504818B1 (ko) 위암에 대한 예후 예측 시스템
HK40107615A (en) Methods to predict clinical outcome of cancer
HK40043378A (en) Methods to predict clinical outcome of cancer
HK1175820B (en) Methods to predict clinical outcome of cancer
HK1175820A (en) Methods to predict clinical outcome of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20170626

Address after: Seoul, South Kerean

Applicant after: Novamax Co.,Ltd.

Address before: Seoul, South Kerean

Applicant before: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI University

GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Seoul, South Kerean

Patentee after: NOVOMICS Co.,Ltd.

Address before: Seoul, South Kerean

Patentee before: Novamax Co.,Ltd.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20171103